These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22473861)

  • 1. Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties.
    Cummings MD; Lin TI; Hu L; Tahri A; McGowan D; Amssoms K; Last S; Devogelaere B; Rouan MC; Vijgen L; Berke JM; Dehertogh P; Fransen E; Cleiren E; van der Helm L; Fanning G; Van Emelen K; Nyanguile O; Simmen K; Raboisson P; Vendeville S
    Angew Chem Int Ed Engl; 2012 May; 51(19):4637-40. PubMed ID: 22473861
    [No Abstract]   [Full Text] [Related]  

  • 2. Discovery of an irreversible HCV NS5B polymerase inhibitor.
    Zeng Q; Nair AG; Rosenblum SB; Huang HC; Lesburg CA; Jiang Y; Selyutin O; Chan TY; Bennett F; Chen KX; Venkatraman S; Sannigrahi M; Velazquez F; Duca JS; Gavalas S; Huang Y; Pu H; Wang L; Pinto P; Vibulbhan B; Agrawal S; Ferrari E; Jiang CK; Li C; Hesk D; Gesell J; Sorota S; Shih NY; Njoroge FG; Kozlowski JA
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6585-7. PubMed ID: 24252545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series.
    McGowan D; Vendeville S; Lin TI; Tahri A; Hu L; Cummings MD; Amssoms K; Berke JM; Canard M; Cleiren E; Dehertogh P; Last S; Fransen E; Van Der Helm E; Van den Steen I; Vijgen L; Rouan MC; Fanning G; Nyanguile O; Van Emelen K; Simmen K; Raboisson P
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4431-6. PubMed ID: 22542193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery and structure-activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase.
    LaPorte MG; Draper TL; Miller LE; Blackledge CW; Leister LK; Amparo E; Hussey AR; Young DC; Chunduru SK; Benetatos CA; Rhodes G; Gopalsamy A; Herbertz T; Burns CJ; Condon SM
    Bioorg Med Chem Lett; 2010 May; 20(9):2968-73. PubMed ID: 20347591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinediones.
    de Vicente J; Hendricks RT; Smith DB; Fell JB; Fischer J; Spencer SR; Stengel PJ; Mohr P; Robinson JE; Blake JF; Hilgenkamp RK; Yee C; Adjabeng G; Elworthy TR; Tracy J; Chin E; Li J; Wang B; Bamberg JT; Stephenson R; Oshiro C; Harris SF; Ghate M; Leveque V; Najera I; Le Pogam S; Rajyaguru S; Ao-Ieong G; Alexandrova L; Larrabee S; Brandl M; Briggs A; Sukhtankar S; Farrell R; Xu B
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3642-6. PubMed ID: 19457662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery and structure-activity relationships of pyrano[3,4-b]indole-based inhibitors of hepatitis C virus NS5B polymerase.
    Jackson RW; LaPorte MG; Herbertz T; Draper TL; Gaboury JA; Rippin SR; Patel R; Chunduru SK; Benetatos CA; Young DC; Burns CJ; Condon SM
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3227-31. PubMed ID: 21550237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055.
    Vendeville S; Lin TI; Hu L; Tahri A; McGowan D; Cummings MD; Amssoms K; Canard M; Last S; Van den Steen I; Devogelaere B; Rouan MC; Vijgen L; Berke JM; Dehertogh P; Fransen E; Cleiren E; van der Helm L; Fanning G; Van Emelen K; Nyanguile O; Simmen K; Raboisson P
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4437-43. PubMed ID: 22633687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinolones as HCV NS5B polymerase inhibitors.
    Kumar DV; Rai R; Brameld KA; Somoza JR; Rajagopalan R; Janc JW; Xia YM; Ton TL; Shaghafi MB; Hu H; Lehoux I; To N; Young WB; Green MJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):82-7. PubMed ID: 21145235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tri-substituted acylhydrazines as tertiary amide bioisosteres: HCV NS5B polymerase inhibitors.
    Canales E; Carlson JS; Appleby T; Fenaux M; Lee J; Tian Y; Tirunagari N; Wong M; Watkins WJ
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4288-92. PubMed ID: 22664130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.
    Stammers TA; Coulombe R; Rancourt J; Thavonekham B; Fazal G; Goulet S; Jakalian A; Wernic D; Tsantrizos Y; Poupart MA; Bös M; McKercher G; Thauvette L; Kukolj G; Beaulieu PL
    Bioorg Med Chem Lett; 2013 May; 23(9):2585-9. PubMed ID: 23545108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides to the hepatitis C virus polymerase.
    Gentles RG; Sheriff S; Beno BR; Wan C; Kish K; Ding M; Zheng X; Chupak L; Poss MA; Witmer MR; Morin P; Wang YK; Rigat K; Lemm J; Voss S; Liu M; Pelosi L; Roberts SB; Gao M; Kadow JF
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2212-5. PubMed ID: 21441029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif.
    Krueger AC; Randolph JT; DeGoey DA; Donner PL; Flentge CA; Hutchinson DK; Liu D; Motter CE; Rockway TW; Wagner R; Beno DW; Koev G; Lim HB; Beyer JM; Mondal R; Liu Y; Kati WM; Longenecker KL; Molla A; Stewart KD; Maring CJ
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3487-90. PubMed ID: 23664214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic amide bioisosterism: strategic application to the design and synthesis of HCV NS5B polymerase inhibitors.
    Yang H; Hendricks RT; Arora N; Nitzan D; Yee C; Lucas MC; Yang Y; Fung A; Rajyaguru S; Harris SF; Leveque VJ; Hang JQ; Pogam SL; Reuter D; Tavares GA
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4614-9. PubMed ID: 20584604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aza follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 1: Mitigating the genotoxic liability of an aniline metabolite.
    Beaulieu PL; Bolger G; Duplessis M; Gagnon A; Garneau M; Stammers T; Kukolj G; Duan J
    Bioorg Med Chem Lett; 2015 Mar; 25(5):1135-9. PubMed ID: 25575656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of a benzodiazepine scaffold yields a potent allosteric inhibitor of hepatitis C NS5B RNA polymerase.
    Vandyck K; Cummings MD; Nyanguile O; Boutton CW; Vendeville S; McGowan D; Devogelaere B; Amssoms K; Last S; Rombauts K; Tahri A; Lory P; Hu L; Beauchamp DA; Simmen K; Raboisson P
    J Med Chem; 2009 Jul; 52(14):4099-102. PubMed ID: 19507864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics.
    Zhang HX; Li Y; Wang X; Xiao ZT; Wang YH
    Curr Med Chem; 2011; 18(26):4019-28. PubMed ID: 21824089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.
    Chen KX; Vibulbhan B; Yang W; Sannigrahi M; Velazquez F; Chan TY; Venkatraman S; Anilkumar GN; Zeng Q; Bennet F; Jiang Y; Lesburg CA; Duca J; Pinto P; Gavalas S; Huang Y; Wu W; Selyutin O; Agrawal S; Feld B; Huang HC; Li C; Cheng KC; Shih NY; Kozlowski JA; Rosenblum SB; Njoroge FG
    J Med Chem; 2012 Jan; 55(2):754-65. PubMed ID: 22148957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.
    Gentles RG; Ding M; Bender JA; Bergstrom CP; Grant-Young K; Hewawasam P; Hudyma T; Martin S; Nickel A; Regueiro-Ren A; Tu Y; Yang Z; Yeung KS; Zheng X; Chao S; Sun JH; Beno BR; Camac DM; Chang CH; Gao M; Morin PE; Sheriff S; Tredup J; Wan J; Witmer MR; Xie D; Hanumegowda U; Knipe J; Mosure K; Santone KS; Parker DD; Zhuo X; Lemm J; Liu M; Pelosi L; Rigat K; Voss S; Wang Y; Wang YK; Colonno RJ; Gao M; Roberts SB; Gao Q; Ng A; Meanwell NA; Kadow JF
    J Med Chem; 2014 Mar; 57(5):1855-79. PubMed ID: 24397558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127).
    LaPlante SR; Bös M; Brochu C; Chabot C; Coulombe R; Gillard JR; Jakalian A; Poirier M; Rancourt J; Stammers T; Thavonekham B; Beaulieu PL; Kukolj G; Tsantrizos YS
    J Med Chem; 2014 Mar; 57(5):1845-54. PubMed ID: 24159919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Molecular Field Analysis and Molecular Docking Studies on Quinolinone Derivatives Indicate Potential Hepatitis C Virus Inhibitors.
    Malathi K; Ramaiah S; Anbarasu A
    Cell Biochem Biophys; 2019 Jun; 77(2):139-156. PubMed ID: 30796723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.